In June, a study supported by the National Cancer Institute found that for people with HIV, early treatment of precancerous anal lesions caused by human papillomavirus (HPV) can cut rates of anal cancer incidence by more than half. These findings from the Anal Cancer/HSIL Outcomes Research (ANCHOR) study are creating secondary prevention options for those at risk for anal cancer who have not received the HPV vaccine. We look into the history of the study and what its work means for those at risk for anal cancer.
Cancer HealthCast
47m listen
An Intersectional Look at Anal Cancer and HIV
NCI’s ANCHOR study discovered that early treatment of precancerous lesions can cut anal cancer rates by more than half in people with HIV.
-
Dr. Joel Palefsky Professor of Medicine University of California San Francisco -
Dr. Robert Yarchoan Director, Office of HIV and AIDS Malignancy NCI
Related Content
-
GSA Cloud Chief Talks FedRAMP 2.0, Automation Hub
Eric Mill shares how a new pilot will inform continuous assessments plus more on software development resources and generative AI.
24m listen -
Boosting the Public Sector Cybersecurity Workforce
ISC2's Tara Wisniewski spoke about skills-based hiring in cybersecurity and how agencies can hire cyber pros easier.
11m listen -
NIST Center Helps Translate Cyber Standards into Practice
Interagency agreements and the collaboration model at the National Cybersecurity Center of Excellence advance cybersecurity.
15m listen -
DISA Using AI to Secure Multi-Cloud Environments
The Defense Information Systems Agency is harnessing artificial intelligence to secure multi-cloud environments.
13m listen
